Meeting
2019 ASCO Annual Meeting
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
Authors
Hope S. Rugo
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
Hope S. Rugo , Manuel Ruiz Borrego , Stephen K. L. Chia , Dejan Juric , Nicholas C. Turner , Pamela Drullinsky , Florence Lerebours , Giulia Valeria Bianchi , Carolyn C. Nienstedt , Antonia Ridolfi , Astrid Thuerigen , Eva Ciruelos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02437318
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1040)
DOI
10.1200/JCO.2019.37.15_suppl.1040
Abstract #
1040
Poster Bd #
121
Abstract Disclosures
Similar Posters
First Author: Michelino De Laurentiis
First Author: Dejan Juric
Poster
2021 ASCO Annual Meeting
Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve.
First Author: Stephen K. L. Chia
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
First Author: Dejan Juric